By Leader Health Editorial Team. Medically Reviewed by Stephen Ratcliff, MD, MBA, Chief Medical Officer. Last reviewed: 2026-07-05.
By Leader Health Editorial Team. Medically Reviewed by Stephen Ratcliff, MD, MBA, Chief Medical Officer. Last reviewed: 2026-07-05.
By Leader Health Editorial Team. Medically Reviewed by Stephen Ratcliff, MD, MBA, Chief Medical Officer. Last reviewed: 2026-07-05.
A physician-reviewed guide to longevity and biological age testing — which biomarkers have real evidence, which are still uncertain, and why context matters.
A physician-reviewed guide to longevity and biological age testing — which biomarkers have real evidence, which are still uncertain, and why context matters.
A physician-reviewed guide to longevity and biological age testing — which biomarkers have real evidence, which are still uncertain, and why context matters.
Biological Age and Longevity Lab Tests: What the Evidence Actually Supports
Biological Age and Longevity Lab Tests: What the Evidence Actually Supports
Labs & Biomarkers
Image is AI-generated and does not represent actual results.
Chief Medical Officer
Stephen Ratcliff, MD
Labs & Biomarkers
Image is AI-generated and does not represent actual results.
Chief Medical Officer
Stephen Ratcliff, MD
Labs & Biomarkers
Image is AI-generated and does not represent actual results.
Chief Medical Officer
Stephen Ratcliff, MD
Key takeaways
“Biological age” has become one of the most-searched ideas in longevity — but the term covers two very different things. A handful of lab and fitness measures — ApoB, lipoprotein(a), HbA1c, cardiorespiratory fitness (VO2 max), and grip strength — have large, replicated data linking them to long-term health outcomes. The branded “biological age” panels marketed most aggressively, such as epigenetic clocks and telomere kits, are scientifically interesting but not yet validated to guide an individual person’s decisions. A single snapshot rarely tells the story; the value is in the trend over time and in a clinician reading the numbers against your symptoms, history, and goals. Here is what the evidence supports, where it is still thin, and how to tell the difference.
If you have spent any time in the longevity corner of the internet, you have seen the pitch: send a few drops of blood or a cheek swab, and an algorithm will hand you your “real” age. Maybe it came back younger than your birthday and felt like a reward for the work you have been putting in. Maybe it came back older and quietly ruined your week.
The instinct behind the trend is a good one. You want to know whether your training, your sleep, and your nutrition are actually moving the needle — and you are right to be skeptical of a healthcare system that waits for disease before it measures much of anything. That frustration is legitimate.
The problem is that “biological age” is doing an enormous amount of work in that sentence. Not all of the tests sold under that banner are measuring the same thing, and some are not measuring anything that has been validated to predict your future. The honest version of this conversation separates the markers with real evidence from the ones still finding their footing.
What “Biological Age” Actually Means
Chronological age is the number of years since you were born. Biological age is an attempt to estimate how worn or resilient your body actually is, independent of that number — the idea being that two 50-year-olds can sit a decade apart in real physiological terms.
In practice, the tests claiming to measure it fall into two families, and the distinction is the whole game.
The first family is a panel of individual markers with established outcome data.These are not exotic. They are measures like apolipoprotein B, lipoprotein(a), HbA1c, cardiorespiratory fitness, and grip strength — each independently linked, in large studies, to the outcomes people care about: heart disease, diabetes, and death from any cause.
The second family is the molecular “clock.” Epigenetic clocks read chemical tags (DNA methylation) on your genome and run them through an algorithm trained to predict age or pace of aging. Telomere tests measure the protective caps on your chromosomes. These are the products most often sold as a single “biological age” number.
The biological story behind the clocks is real: methylation patterns do change in patterned ways as we age, and the research-grade versions of these tools track meaningful biology. But “the biology is real” and “this specific consumer test should change what you do” are different claims, and most of the marketing blurs them.
The Biomarkers With Real Evidence Behind Them
If the goal is to spend your testing dollars where the data is strongest, this is the short list. Each of these has either large outcome studies, a current society guideline, or both.
Apolipoprotein B (ApoB). ApoB counts the actual number of cholesterol-carrying particles capable of lodging in an artery wall — a more direct measure of atherogenic burden than the standard LDL cholesterol value, which can understate true particle count in people with insulin resistance, high triglycerides, or type 2 diabetes — settings in which LDL particles tend to be smaller and more numerous than the cholesterol number suggests. This mismatch — called discordance — is common in insulin resistance, and it is the reason ApoB can add information the cholesterol number misses. In the 2026 ACC/AHA/multisociety dyslipidemia guideline, ApoB measurement is now considered reasonable (Class IIa) to improve risk assessment and guide further therapy once LDL-C and non–HDL-C goals are met — particularly in adults with elevated triglycerides (>200 mg/dL), diabetes, or a low achieved LDL-C (<70 mg/dL), settings in which the standard number can understate residual particle-related risk (2026 ACC/AHA Guideline).
Lipoprotein(a), or Lp(a). Lp(a) is largely set by your genes and stays stable across life, which is why the same 2026 guideline now recommends measuring it at least once in every adult — its strongest (Class I) new recommendation. A level of 125 nmol/L or higher (roughly 50 mg/dL) is associated with about a 1.4-fold higher long-term risk of heart attack or stroke; risk rises along a continuum, roughly doubling at 250 nmol/L and quadrupling at very high levels. Because it barely moves with lifestyle, one measurement usually answers the question for life (2026 ACC/AHA Guideline).
HbA1c. HbA1c reflects your average blood sugar over roughly three months. The American Diabetes Association uses 5.7–6.4% to define prediabetes and 6.5% or above for diabetes — a window that often opens years before a fasting glucose looks abnormal (ADA Standards of Care).
Fasting insulin. Insulin tends to climb to keep glucose normal long before glucose itself drifts up, so a fasting insulin can flag insulin resistance earlier than a glucose or HbA1c alone. The evidence here is more about mechanism and trend than a single validated cut-point, so it is best read in context rather than as a verdict.
High-sensitivity CRP (hsCRP). hsCRP is a marker of low-grade inflammation, and the same 2026 ACC/AHA guideline lists an hsCRP of 2 mg/L or higher as a risk-enhancing factor that can support a decision to treat more aggressively (2026 ACC/AHA Guideline).
None of these is a “biological age” in the marketing sense. They are something more useful: specific, modifiable signals, each tied to a specific risk, that a clinician can actually act on.
The Two Markers You Can Actually Train: VO2 Max and Grip Strength
Two of the most predictive measures of long-term health are not blood tests at all — and both respond to training, which is what makes them worth tracking.
Cardiorespiratory fitness, often expressed as VO2 max, has one of the strongest associations with survival in the entire literature. In a Cleveland Clinic analysis of 122,007 adults, all-cause mortality fell stepwise as fitness rose. Adults with below-average fitness had about a 41% higher mortality risk than those above average (HR 1.41) — a signal comparable in size to smoking (HR 1.41), coronary artery disease (HR 1.29), or diabetes (HR 1.40). At the extremes, participants in the lowest fitness category carried roughly five times the mortality risk of the top ~2.5% (HR 5.04), with no observed upper limit of benefit (Mandsager 2018, PMID 30646252). The study is observational, so it establishes a powerful association rather than proof that raising VO2 max directly extends life; the mechanistic case, however, is strong and the signal is hard to ignore.
Grip strength tells a similar story for muscle. In over 500,000 UK Biobank participants, each 5 kg lower grip strength was associated with roughly 16% higher all-cause mortality in men and 20% in women, and adding grip strength improved a standard office-based risk score (Celis-Morales 2018, PMID 29739772). A meta-analysis of more than three million people found the same direction of effect (Wu 2017, PMID 28549705). Grip strength is a proxy for total-body strength, not a magic number — but it is cheap, repeatable, and trainable.
Where the Evidence Gets Thin: Epigenetic Clocks and Biological-Age Panels
This is the part most longevity marketing skips. The research behind epigenetic clocks is genuinely interesting. A well-constructed tool called DunedinPACE, built from a long-running birth-cohort study, tracks a “pace of aging” from a blood sample and has been validated against later morbidity, disability, and mortality in cohort data (Belsky 2022, PMID 35029144; with further validation in subsequent cohort studies). That is real science.
The honest limitation is the gap between that research and the test you can buy. Independent reporting has found that consumer biological-age products can return widely different ages for the same person, that companies often do not disclose which clock they use, and that many saliva-based consumer kits lack the outcome validation the blood-based research clocks have. A research tool that predicts outcomes across thousands of people is not the same as a consumer test validated to tell you, specifically, what to do this year. Telomere-length kits sit in the same category: telomere measurement varies considerably depending on the laboratory method used, which limits how much weight a single consumer result can carry.
What the evidence does not support is treating a single “biological age” readout as a verdict, or as a reason to buy whatever protocol is sold alongside it. That caution is not just editorial. In June 2026, the Federal Trade Commission sued a supplement MLM for marketing products as “clinically proven” for depression, anxiety and ADHD — and shortly after moved to hold the company in contempt of a 2005 order for the same conduct — a reminder that “backed by science” and “proven for you” are not the same claim (FTC, June 2026). Anyone selling a biological-age number as a settled measure of how long you will live is overstating what the science currently supports.
Why a Single Snapshot Rarely Tells the Story
Even the strongest markers are easy to misread in isolation. A one-time ApoB tells you less than the same number measured before and after six months of changes. A VO2 max is only meaningful against your own prior result and your age and sex norms. And the more tests you run, the more likely it is that something comes back mildly out of range by chance — a finding that can generate anxiety, a cascade of follow-up testing, and no actual benefit.
This is the difference between a data dump and a plan. A panel of 100 biomarkers ordered without context produces orphaned findings: a number flagged in red, no one to interpret it, and no sense of whether it matters for you. The clinical reality is that the same lab value can be reassuring in one person and worth acting on in another, depending on symptoms, family history, medications, and goals. The signal worth taking seriously is the trend over time, read by someone who knows the rest of your picture.
How Leader Health Approaches This
At Leader Health, lab testing is part of a physician-supervised program — not a standalone panel you are left to decode on your own. We focus on the markers with real evidence behind them, we read them against your symptoms, history, and goals, and we track the trend over time rather than treating a single snapshot as a verdict.
If you have been curious about longevity testing but are tired of marketing that sells a number and a supplement in the same breath, this is the conversation worth having. Your intake includes a baseline panel and a physician who will tell you plainly which results matter for you and which do not.
References
Mandsager K, Harb S, Cremer P, et al. Association of Cardiorespiratory Fitness With Long-term Mortality Among Adults Undergoing Exercise Treadmill Testing. JAMA Netw Open. 2018;1(6):e183605. PMID: 30646252. pubmed.ncbi.nlm.nih.gov/30646252/
Celis-Morales CA, Welsh P, Lyall DM, et al. Associations of grip strength with cardiovascular, respiratory, and cancer outcomes and all cause mortality: prospective cohort study of half a million UK Biobank participants. BMJ. 2018;361:k1651. PMID: 29739772. pubmed.ncbi.nlm.nih.gov/29739772/
Wu Y, Wang W, Liu T, Zhang D. Association of Grip Strength With Risk of All-Cause Mortality, Cardiovascular Diseases, and Cancer: A Meta-analysis of Prospective Cohort Studies. J Am Med Dir Assoc. 2017;18(6):551.e17-551.e35. PMID: 28549705. pubmed.ncbi.nlm.nih.gov/28549705/
Belsky DW, Caspi A, Corcoran DL, et al. DunedinPACE, a DNA methylation biomarker of the pace of aging. eLife. 2022;11:e73420. PMID: 35029144. pubmed.ncbi.nlm.nih.gov/35029144/
Writing Committee, American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. 2026 ACC/AHA/Multisociety Guideline on the Management of Dyslipidemia. Circulation. 2026. DOI: 10.1161/CIR.0000000000001423. ahajournals.org/doi/10.1161/CIR.0000000000001423 See also AHA “Top Things to Know: 2026 Guideline on the Management of Dyslipidemia,” item 5. professional.heart.org/en/science-news/2026-guideline-on-the-management-of-dyslipidemia/top-things-to-know
American Diabetes Association. Standards of Care in Diabetes—2026. Section 2: Diagnosis and Classification of Diabetes. Diabetes Care. 2026;49(Suppl 1). diabetesjournals.org/care
Federal Trade Commission. FTC Sues to Stop Amare Global Holdings from Misrepresenting the Health Benefits of Its Dietary Supplements. June 2026. ftc.gov/news-events/news/press-releases/2026/06/ See also: FTC seeks contempt against Amare Global for alleged violation of a 2005 order, June 12, 2026. andrewandhopkins.com/insights/client-alerts/ftc-seeks-contempt-against-amare-global
Key takeaways
“Biological age” has become one of the most-searched ideas in longevity — but the term covers two very different things. A handful of lab and fitness measures — ApoB, lipoprotein(a), HbA1c, cardiorespiratory fitness (VO2 max), and grip strength — have large, replicated data linking them to long-term health outcomes. The branded “biological age” panels marketed most aggressively, such as epigenetic clocks and telomere kits, are scientifically interesting but not yet validated to guide an individual person’s decisions. A single snapshot rarely tells the story; the value is in the trend over time and in a clinician reading the numbers against your symptoms, history, and goals. Here is what the evidence supports, where it is still thin, and how to tell the difference.
If you have spent any time in the longevity corner of the internet, you have seen the pitch: send a few drops of blood or a cheek swab, and an algorithm will hand you your “real” age. Maybe it came back younger than your birthday and felt like a reward for the work you have been putting in. Maybe it came back older and quietly ruined your week.
The instinct behind the trend is a good one. You want to know whether your training, your sleep, and your nutrition are actually moving the needle — and you are right to be skeptical of a healthcare system that waits for disease before it measures much of anything. That frustration is legitimate.
The problem is that “biological age” is doing an enormous amount of work in that sentence. Not all of the tests sold under that banner are measuring the same thing, and some are not measuring anything that has been validated to predict your future. The honest version of this conversation separates the markers with real evidence from the ones still finding their footing.
What “Biological Age” Actually Means
Chronological age is the number of years since you were born. Biological age is an attempt to estimate how worn or resilient your body actually is, independent of that number — the idea being that two 50-year-olds can sit a decade apart in real physiological terms.
In practice, the tests claiming to measure it fall into two families, and the distinction is the whole game.
The first family is a panel of individual markers with established outcome data.These are not exotic. They are measures like apolipoprotein B, lipoprotein(a), HbA1c, cardiorespiratory fitness, and grip strength — each independently linked, in large studies, to the outcomes people care about: heart disease, diabetes, and death from any cause.
The second family is the molecular “clock.” Epigenetic clocks read chemical tags (DNA methylation) on your genome and run them through an algorithm trained to predict age or pace of aging. Telomere tests measure the protective caps on your chromosomes. These are the products most often sold as a single “biological age” number.
The biological story behind the clocks is real: methylation patterns do change in patterned ways as we age, and the research-grade versions of these tools track meaningful biology. But “the biology is real” and “this specific consumer test should change what you do” are different claims, and most of the marketing blurs them.
The Biomarkers With Real Evidence Behind Them
If the goal is to spend your testing dollars where the data is strongest, this is the short list. Each of these has either large outcome studies, a current society guideline, or both.
Apolipoprotein B (ApoB). ApoB counts the actual number of cholesterol-carrying particles capable of lodging in an artery wall — a more direct measure of atherogenic burden than the standard LDL cholesterol value, which can understate true particle count in people with insulin resistance, high triglycerides, or type 2 diabetes — settings in which LDL particles tend to be smaller and more numerous than the cholesterol number suggests. This mismatch — called discordance — is common in insulin resistance, and it is the reason ApoB can add information the cholesterol number misses. In the 2026 ACC/AHA/multisociety dyslipidemia guideline, ApoB measurement is now considered reasonable (Class IIa) to improve risk assessment and guide further therapy once LDL-C and non–HDL-C goals are met — particularly in adults with elevated triglycerides (>200 mg/dL), diabetes, or a low achieved LDL-C (<70 mg/dL), settings in which the standard number can understate residual particle-related risk (2026 ACC/AHA Guideline).
Lipoprotein(a), or Lp(a). Lp(a) is largely set by your genes and stays stable across life, which is why the same 2026 guideline now recommends measuring it at least once in every adult — its strongest (Class I) new recommendation. A level of 125 nmol/L or higher (roughly 50 mg/dL) is associated with about a 1.4-fold higher long-term risk of heart attack or stroke; risk rises along a continuum, roughly doubling at 250 nmol/L and quadrupling at very high levels. Because it barely moves with lifestyle, one measurement usually answers the question for life (2026 ACC/AHA Guideline).
HbA1c. HbA1c reflects your average blood sugar over roughly three months. The American Diabetes Association uses 5.7–6.4% to define prediabetes and 6.5% or above for diabetes — a window that often opens years before a fasting glucose looks abnormal (ADA Standards of Care).
Fasting insulin. Insulin tends to climb to keep glucose normal long before glucose itself drifts up, so a fasting insulin can flag insulin resistance earlier than a glucose or HbA1c alone. The evidence here is more about mechanism and trend than a single validated cut-point, so it is best read in context rather than as a verdict.
High-sensitivity CRP (hsCRP). hsCRP is a marker of low-grade inflammation, and the same 2026 ACC/AHA guideline lists an hsCRP of 2 mg/L or higher as a risk-enhancing factor that can support a decision to treat more aggressively (2026 ACC/AHA Guideline).
None of these is a “biological age” in the marketing sense. They are something more useful: specific, modifiable signals, each tied to a specific risk, that a clinician can actually act on.
The Two Markers You Can Actually Train: VO2 Max and Grip Strength
Two of the most predictive measures of long-term health are not blood tests at all — and both respond to training, which is what makes them worth tracking.
Cardiorespiratory fitness, often expressed as VO2 max, has one of the strongest associations with survival in the entire literature. In a Cleveland Clinic analysis of 122,007 adults, all-cause mortality fell stepwise as fitness rose. Adults with below-average fitness had about a 41% higher mortality risk than those above average (HR 1.41) — a signal comparable in size to smoking (HR 1.41), coronary artery disease (HR 1.29), or diabetes (HR 1.40). At the extremes, participants in the lowest fitness category carried roughly five times the mortality risk of the top ~2.5% (HR 5.04), with no observed upper limit of benefit (Mandsager 2018, PMID 30646252). The study is observational, so it establishes a powerful association rather than proof that raising VO2 max directly extends life; the mechanistic case, however, is strong and the signal is hard to ignore.
Grip strength tells a similar story for muscle. In over 500,000 UK Biobank participants, each 5 kg lower grip strength was associated with roughly 16% higher all-cause mortality in men and 20% in women, and adding grip strength improved a standard office-based risk score (Celis-Morales 2018, PMID 29739772). A meta-analysis of more than three million people found the same direction of effect (Wu 2017, PMID 28549705). Grip strength is a proxy for total-body strength, not a magic number — but it is cheap, repeatable, and trainable.
Where the Evidence Gets Thin: Epigenetic Clocks and Biological-Age Panels
This is the part most longevity marketing skips. The research behind epigenetic clocks is genuinely interesting. A well-constructed tool called DunedinPACE, built from a long-running birth-cohort study, tracks a “pace of aging” from a blood sample and has been validated against later morbidity, disability, and mortality in cohort data (Belsky 2022, PMID 35029144; with further validation in subsequent cohort studies). That is real science.
The honest limitation is the gap between that research and the test you can buy. Independent reporting has found that consumer biological-age products can return widely different ages for the same person, that companies often do not disclose which clock they use, and that many saliva-based consumer kits lack the outcome validation the blood-based research clocks have. A research tool that predicts outcomes across thousands of people is not the same as a consumer test validated to tell you, specifically, what to do this year. Telomere-length kits sit in the same category: telomere measurement varies considerably depending on the laboratory method used, which limits how much weight a single consumer result can carry.
What the evidence does not support is treating a single “biological age” readout as a verdict, or as a reason to buy whatever protocol is sold alongside it. That caution is not just editorial. In June 2026, the Federal Trade Commission sued a supplement MLM for marketing products as “clinically proven” for depression, anxiety and ADHD — and shortly after moved to hold the company in contempt of a 2005 order for the same conduct — a reminder that “backed by science” and “proven for you” are not the same claim (FTC, June 2026). Anyone selling a biological-age number as a settled measure of how long you will live is overstating what the science currently supports.
Why a Single Snapshot Rarely Tells the Story
Even the strongest markers are easy to misread in isolation. A one-time ApoB tells you less than the same number measured before and after six months of changes. A VO2 max is only meaningful against your own prior result and your age and sex norms. And the more tests you run, the more likely it is that something comes back mildly out of range by chance — a finding that can generate anxiety, a cascade of follow-up testing, and no actual benefit.
This is the difference between a data dump and a plan. A panel of 100 biomarkers ordered without context produces orphaned findings: a number flagged in red, no one to interpret it, and no sense of whether it matters for you. The clinical reality is that the same lab value can be reassuring in one person and worth acting on in another, depending on symptoms, family history, medications, and goals. The signal worth taking seriously is the trend over time, read by someone who knows the rest of your picture.
How Leader Health Approaches This
At Leader Health, lab testing is part of a physician-supervised program — not a standalone panel you are left to decode on your own. We focus on the markers with real evidence behind them, we read them against your symptoms, history, and goals, and we track the trend over time rather than treating a single snapshot as a verdict.
If you have been curious about longevity testing but are tired of marketing that sells a number and a supplement in the same breath, this is the conversation worth having. Your intake includes a baseline panel and a physician who will tell you plainly which results matter for you and which do not.
References
Mandsager K, Harb S, Cremer P, et al. Association of Cardiorespiratory Fitness With Long-term Mortality Among Adults Undergoing Exercise Treadmill Testing. JAMA Netw Open. 2018;1(6):e183605. PMID: 30646252. pubmed.ncbi.nlm.nih.gov/30646252/
Celis-Morales CA, Welsh P, Lyall DM, et al. Associations of grip strength with cardiovascular, respiratory, and cancer outcomes and all cause mortality: prospective cohort study of half a million UK Biobank participants. BMJ. 2018;361:k1651. PMID: 29739772. pubmed.ncbi.nlm.nih.gov/29739772/
Wu Y, Wang W, Liu T, Zhang D. Association of Grip Strength With Risk of All-Cause Mortality, Cardiovascular Diseases, and Cancer: A Meta-analysis of Prospective Cohort Studies. J Am Med Dir Assoc. 2017;18(6):551.e17-551.e35. PMID: 28549705. pubmed.ncbi.nlm.nih.gov/28549705/
Belsky DW, Caspi A, Corcoran DL, et al. DunedinPACE, a DNA methylation biomarker of the pace of aging. eLife. 2022;11:e73420. PMID: 35029144. pubmed.ncbi.nlm.nih.gov/35029144/
Writing Committee, American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. 2026 ACC/AHA/Multisociety Guideline on the Management of Dyslipidemia. Circulation. 2026. DOI: 10.1161/CIR.0000000000001423. ahajournals.org/doi/10.1161/CIR.0000000000001423 See also AHA “Top Things to Know: 2026 Guideline on the Management of Dyslipidemia,” item 5. professional.heart.org/en/science-news/2026-guideline-on-the-management-of-dyslipidemia/top-things-to-know
American Diabetes Association. Standards of Care in Diabetes—2026. Section 2: Diagnosis and Classification of Diabetes. Diabetes Care. 2026;49(Suppl 1). diabetesjournals.org/care
Federal Trade Commission. FTC Sues to Stop Amare Global Holdings from Misrepresenting the Health Benefits of Its Dietary Supplements. June 2026. ftc.gov/news-events/news/press-releases/2026/06/ See also: FTC seeks contempt against Amare Global for alleged violation of a 2005 order, June 12, 2026. andrewandhopkins.com/insights/client-alerts/ftc-seeks-contempt-against-amare-global
In this article
Frequently Asked Questions
It depends entirely on which test. Markers like ApoB, lipoprotein(a), HbA1c, VO2 max, and grip strength have large, replicated studies linking them to real outcomes. The single-number "biological age" products — epigenetic clocks and telomere kits — are built on real science but, in their consumer form, have been reported to return inconsistent results across commercial providers and are not yet validated to guide an individual's decisions.
For cardiovascular and metabolic risk, the highest-evidence measures are ApoB, lipoprotein(a) (once in a lifetime), HbA1c, and fasting insulin. For overall resilience, cardiorespiratory fitness (VO2 max) and grip strength are among the most predictive measures in the literature — and both can be improved with training.
They can be a reasonable starting point, and the trend toward affordable testing is a good one. The limitation is interpretation: a large panel produces data, not a plan, and an out-of-range value with no clinical context can create more worry than insight. The value comes from someone reading the results against your symptoms, history, and goals — and tracking them over time.
A standard panel estimates the amount of cholesterol in your LDL particles. ApoB counts the particles themselves — the actual number capable of entering an artery wall. When those two numbers disagree, which is common in people with diabetes or high triglycerides, ApoB is often the more accurate read on risk, which is why the 2026 ACC/AHA guideline now recommends it in those situations.
It varies by marker. Lipoprotein(a) is largely genetic and stable, so once is usually enough. ApoB, HbA1c, and fasting insulin are worth rechecking when you change something — a medication, your training, your diet — to see whether it worked, typically every few months to once a year. A physician can set the right cadence for your situation rather than testing everything on a fixed schedule.
You can improve most of the markers that matter: fitness, strength, ApoB, HbA1c, and fasting insulin all respond to training, nutrition, and, where appropriate, medication. Whether moving those markers changes a single "biological age" number, or changes how long you live, is a separate and less settled question. The reasonable goal is to improve the measures with outcome evidence behind them, not to chase a clock reading.
For a single screening number, not always. But the value of testing comes from context — knowing which result matters for you, what to do about it, and how it is trending. That interpretation, not the raw data, is where physician-led care differs from a standalone panel.
About Medical Reviewer
About Medical Reviewer
Stephen Ratcliff, MD is the Chief Medical Officer of Leader Health and the board-certified physician responsible for clinical governance, medical content review, and regulatory oversight across the platform. Every article on the Leader Health blog is reviewed and approved by Dr. Ratcliff before publication.
Stephen Ratcliff, MD is the Chief Medical Officer of Leader Health and the board-certified physician responsible for clinical governance, medical content review, and regulatory oversight across the platform. Every article on the Leader Health blog is reviewed and approved by Dr. Ratcliff before publication.
Stephen Ratcliff, MD is the Chief Medical Officer of Leader Health and the board-certified physician responsible for clinical governance, medical content review, and regulatory oversight across the platform. Every article on the Leader Health blog is reviewed and approved by Dr. Ratcliff before publication.
Stephen Ratcliff, MD, MBA
CMO of Leader Health
All related stories post
All related stories post
Keep reading — physician-reviewed insights on the topics that connect to your health goals.
Keep reading — physician-reviewed insights on the topics that connect to your health goals.
Estrogen Hard to Fill? Your Hormone Therapy Options When a Format Runs Short
A physician-reviewed guide to estrogen delivery options when your patch is hard to fill — how patch, gel, spray, oral, and vaginal routes compare, and how to switch safely. Primary keyword: estradiol patch shortage (est. 20,000-35,000/mo, spiking)
Recovery Peptides: Separating the Evidence From the Hype (and Where the FDA Stands)
A physician-reviewed look at recovery peptides — what is actually studied versus marketed, the anti-doping reality, and what the FDA's 2026 compounding review does and doesn't change.
Is It Perimenopause or Low Desire? How to Read the Signals Together
A physician-reviewed guide to telling perimenopause-driven low desire from primary low libido — the overlapping signals, and how a clinician sorts them out.
All related stories post
Keep reading — physician-reviewed insights on the topics that connect to your health goals.
Estrogen Hard to Fill? Your Hormone Therapy Options When a Format Runs Short
A physician-reviewed guide to estrogen delivery options when your patch is hard to fill — how patch, gel, spray, oral, and vaginal routes compare, and how to switch safely. Primary keyword: estradiol patch shortage (est. 20,000-35,000/mo, spiking)
Recovery Peptides: Separating the Evidence From the Hype (and Where the FDA Stands)
A physician-reviewed look at recovery peptides — what is actually studied versus marketed, the anti-doping reality, and what the FDA's 2026 compounding review does and doesn't change.
Is It Perimenopause or Low Desire? How to Read the Signals Together
A physician-reviewed guide to telling perimenopause-driven low desire from primary low libido — the overlapping signals, and how a clinician sorts them out.
CONTACT US
Real People.
Real Answers.
HORMONE THERAPY
WEIGHT LOSS & LONGEVITY
DIAGNOSTIC LABS
COMPANY
TAKE ACTION
STAY INFORMED
Get more from Leader
Compounded medications are prepared by licensed pharmacies and are not FDA-approved. Prescriptions issued only after evaluation by a licensed provider. © 2026 Leader Health, Inc.
CONTACT US
Real People.
Real Answers.
Hormone Therapy
Sexual health
Weight Loss & Longevity
Diagnostic Labs
Company
Take Action
More From Leader
STAY INFORMED
Get more from Leader
Compounded medications are prepared by licensed pharmacies and are not FDA-approved. Prescriptions issued only after evaluation by a licensed provider. © 2026 Leader Health, Inc.
STAY INFORMED
Get more from Leader
Compounded medications are prepared by licensed pharmacies and are not FDA-approved. Prescriptions issued only after evaluation by a licensed provider. © 2026 Leader Health, Inc.
CONTACT US
Real People.
Real Answers.
HORMONE THERAPY
WEIGHT LOSS & LONGEVITY
DIAGNOSTIC LABS
COMPANY
TAKE ACTION